Past Studies

A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Cancer patients with defects in homologous recombination repair can potentially benefit from Poly (ADP-ribose) polymerase (PARP) inhibitors, while other patients show no response. Yet, the identification of these patients is so difficult that it is not being done prior to treatment. We hypothesize that q-PADDA can detect high levels of DNA damage in these patients, and thus, could be used to identify patients with a higher chance of benefiting from these targeted therapies. We are testing that hypothesis as part of this study. The study is a prospective, single-arm, open-label phase II clinical trial conducted at three sites: SCC OUHSC (lead site), University of Minnesota, and University of Virginia. Enrollment is complete.